MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2024 International Congress

    Investigating the genetic relationship between vitamin B12 deficiency and Parkinson’s disease

    K. Senkevich, R. Dering, M. Onvumere, L. Liu, P. Huot, Z. Gan-Or (Montreal, Canada)

    Objective: The aim of this study was to investigate the genetic association and causal link between vitamin B12 and the risk and progression of Parkinson's…
  • 2024 International Congress

    The 201 Trial in Untreated Parkinson’s Disease

    M. Werner, CW. Olanow, A. Mcgarry, C. Meyer, E. Mancino, C. Klint, J. Pellecchia (Atlanta, USA)

    Objective: To evalute the safety, tolerability, clinical benefit and protein pathology status following risvodetinib (IkT-148009) treatment in participants with untreated Parkinson's disease. Background: RIsvodetinib is…
  • 2024 International Congress

    the role of the “unfolded protein response” and the perk pathway in parkinson’s disease: study of genetic polymorphisms

    N. Palomba, E. Bianchini, D. Rinaldi, C. Strafella, V. Caputo, F. Garramone, P. Lombardo, F. Nicoletti, E. Giardina, T. Esposito, F. Pontieri, M. Alborghetti ()

    Objective: To study a possible association between polymorphisms of the genes coding for proteins involved in the UPR and the development of PD or PD…
  • 2024 International Congress

    GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation

    O. Siemeling, S. Slingerland, S. V/d Zee, T. van Laar (Groningen, Netherlands)

    Objective: To study the potential disease-modifying properties of ambroxol in PD patients with a GBA1 mutation Background: The most common genetic risk factor for Parkinson’s…
  • 2024 International Congress

    DPPX Autoimmune Encephalitis Associated with Severe Multifocal Dystonia.

    E. Roddy, E. Gentry, P. Hedera, V. Holiday, D. Robertson (LOUISVILLE, USA)

    Objective: To describe a novel motor phenomenology in an individual diagnosed with anti-DPPX encephalitis at our institution and to compare it with previously known phenotypic…
  • 2024 International Congress

    Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial

    E. Mitchell (London, United Kingdom)

    Objective: Slow-SPEED-UK is a randomized controlled trial investigating the effects of an app-based exercise program on individuals at higher risk of Parkinson’s Disease (PD). Background:…
  • 2024 International Congress

    The NINDS Approach to Therapeutic Development for Ultra-Rare Neurological Disorders, Bridging Translational and Clinical Frontiers in Gene-based Therapy

    HJ. Cho, A. Videnovic, M. Cudkowicz, C. Coffey, D. Klements, M. Chase, J. Ohayon, C. Boshoff, A. Tamiz, C. Wright (Rockville, USA)

    Objective: To establish an innovative process for fast and efficient pathways of delivering gene-based therapy for ultra-rare neurological disorders from the lab to the clinic…
  • 2024 International Congress

    Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins

    C. Murray, C. Kusiak, A. Vanderbeek, D. Bertolini, E. Tramel (San Francisco, USA)

    Objective: To evaluate the incorporation of prognostic digital twins to enhance traditional clinical trials in Parkinson’s Disease (PD) for disease modifying therapies. We assess the…
  • 2024 International Congress

    Muscle Augmentation Paradox: Contrasting Therapeutic Approaches in Myasthenia Gravis and Parkinson’s Disease

    G. Legerme, D. Nolasco, A. Sohel, A. Wu, B. Carr (Gainesville, USA)

    Objective: This exploration aims to dissect the therapeutic paradox presented by muscle augmentation strategies in Myasthenia Gravis (MG) and Parkinson's Disease (PD), offering a comparative…
  • 2024 International Congress

    Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.

    T. Guttuso, JR., R. Shepherd (Williamsville, USA)

    Objective: To assess the effects of lithium aspartate and lithium carbonate therapy for 24 weeks on serum NfL in Parkinson’s disease (PD). Background: Lithium has…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 16
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley